No Data
No Data
Getein Biotech, Inc (SHSE:603387) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
The Getein Biotech, Inc (SHSE:603387) share price has fared very poorly over the last month, falling by a substantial 25%. Instead of being rewarded, shareholders who have already held through the
Retail Investors Among Getein Biotech, Inc's (SHSE:603387) Largest Stockholders and Were Hit After Last Week's 8.1% Price Drop
Key Insights Getein Biotech's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business is held by the top 25 s
BaseEgg Biology (603387.SH): The current luminescence collection project in Anhui accounts for a small proportion of the company's current luminescence reagent project revenue
On November 8, Gelonghui (603387.SH) said at the online performance briefing that judging from the company's chemiluminescence reagent revenue structure, the myocardial category accounts for 85%, and inflammation and tumors account for about 10% in total. At this stage, chemiluminescence mainly focuses on myocardial and inflammation tests. In the future, with the gradual coverage of small assembly line installations, it will drive an increase in testing items such as infectious diseases, hypertonics, and tumors. This time, the Anhui luminescence collection project accounts for a small proportion of the company's current luminescence reagent project revenue, and has little impact on the company's chemiluminescence business.
603387.SH released third quarter results, net profit of 603.497 million yuan, a year-on-year decrease of 58.49%
Kibao Biotech (603387.SH) released its report for the third quarter of 2023, with revenue of 298 million yuan...
Getein Biotech, Inc's (SHSE:603387) Market Cap Dropped CN¥370m Last Week; Individual Investors Bore the Brunt
Key Insights Significant control over Getein Biotech by individual investors implies that the general public has more power to influence management and governance-related decisions A total of 15 inv
Jiegang Biotech (603387.SH) plans to pay 0.1 yuan per share for half a year, excluding interest on September 27
Jiegg Biology (603387.SH) announced that the company plans to distribute a cash dividend of 0.1 yuan per share for the first half year of 2023...
No Data